阿扎胞苷在与骨髓增生异常综合征和慢性粒单核细胞白血病相关的自身免疫性和炎症性疾病中的疗效。
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
作者信息
Fraison Jean-Baptiste, Mekinian Arsène, Grignano Eric, Kahn Jean-Emmanuel, Arlet Jean-Benoit, Decaux Olivier, Denis Guillaume, Buchdahl Anne-Laure, Omouri Mohamed, Maigne Gwenola, Aouba Achille, Leon Nathalie, Berthier Sabine, Liozon Eric, Park Sophie, Gardin Claude, Lortholary Olivier, Rossignol Julien, Fenaux Pierre, Fain Olivier, Braun Thorsten
机构信息
Service de Médecine Interne, Hôpital Jean Verdier, Assistance Publique des Hôpitaux de Paris, Université Paris XIII, France.
Service de Médecine Interne, DHU i2B, Inflammation-Immunopathologie-Biothérapie (DHU i2B), Hôpital Saint Antoine, Assistance Publique des Hôpitaux de Paris, Université Paris VI Sorbonne, 75012 Paris, France.
出版信息
Leuk Res. 2016 Apr;43:13-7. doi: 10.1016/j.leukres.2016.02.005. Epub 2016 Feb 20.
This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n=11), both unfavorable (n=2), but AID improved while MDS/CMML worsened (n=8) and vice versa (n=1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings.
这项回顾性研究描述了阿扎胞苷对22例与骨髓增生异常综合征/慢性粒-单核细胞白血病（MDS/CMML）相关的自身免疫性疾病（AID）的疗效。19例患者（86%）观察到AID对阿扎胞苷有反应。16例（73%）患者有可能减少或停用类固醇和/或免疫抑制治疗（IST）。55%的患者出现血液学反应。13例（59%）患者的MDS/CMML和AID进展一致：均为有利（n = 11），均为不利（n = 2），但AID改善而MDS/CMML恶化（n = 8），反之亦然（n = 1）。阿扎胞苷似乎经常有效地控制与MDS/CMML相关的类固醇依赖性AID，但需要前瞻性研究来证实这些发现。
Zotero 插件